The U.S. Supreme Court has declined to take up industry challenges to the Inflation Reduction Act’s Medicare drug price negotiation program, rejecting petitions from AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Novo Nordisk, Novartis, and Boehringer Ingelheim. The Court’s Monday order follows a series of lower-court defeats for these manufacturers, including AstraZeneca’s loss before the Third Court of Appeals last spring. That case, elevated to the Supreme Court in November, centered on claims that the IRA stripped the company of “investment-backed patent rights” and forced below‑market pricing. Novo Nordisk called the outcome “disappointing” and signaled it would keep working with policymakers over what it describes as government “price setting.”
With the high court’s decision, the pharmaceutical industry’s legal campaign against the IRA has effectively run its course. The Biden-era framework now solidifies the Centers for Medicare and Medicaid Services’ authority to set ceiling prices on costly Medicare drugs, free from further judicial challenge. From here, drugmakers will likely redirect energy from litigation to negotiation itself, seeking leverage inside the process while lobbying Congress and the administration on how the next rounds are shaped. This outcome also strengthens CMS’s hand in advance of President Trump’s proposed “Most Favored Nation” policy talks, which aim to capture roughly $529 billion in additional savings through continued pricing reforms.
Whether the Supreme Court’s choice reflects true acceptance of the IRA’s design or simple procedural restraint, the political message is clear enough: the government’s bargaining power just gained a lasting imprimatur. The results for the market are uneven. Expect short-term noise in Medicare revenue forecasts as companies adjust modeling assumptions. Pharmacy benefit managers and plan sponsors, meanwhile, are already watching how upcoming CMS negotiation lists will alter formulary math. The data is mixed, and no one knows yet how far this shift will ripple through commercial markets, but the direction of travel is obvious. For ongoing analysis of drug pricing mechanics, see RxInfo.ai. I’ll admit, for once, Washington didn’t blink.
